California Prop 14 would keep taxpayer funding of stem cell therapy research, which can change lives: Meet the Langenhop kids – AZCentral.com
Posted: November 4, 2020 at 11:59 am
18-year-old Keely Campbell pays it forward by donating her stem cells 10 years after her dad's transplant. USA TODAY
Three-year-old Ava was constantly sick. Her gums were inflamed, and every time she got a scraped knee, it turned into a dangerous infection.
Her parents, Alicia and Jon Langenhop, were months pregnant with their third child when they learned that Ava's constellation of symptoms added up to an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesiondeficiency-1. Although antibiotics and antivirals could prolong her life, the disease was considered fatal, usually before kindergarten.
Ava's primary hope, doctors told the Langenhops, was a bone marrow transplant from someone who was a good match, probably a brother or a sister.
Two-year-old Olivia had inherited the same disease as her big sister. She had been hospitalized with infections, too.
The baby in Alicias belly would be the girls best hope. Since both parents were carriers of the rare genetic mutation, the new baby, a boy, had a 25% chance of inheriting it, too.
Alicia was still in the hospital last October when they found out baby Landon had the mutation. Around the same time, the couple learned of a research trial in California.
Children Ava, Olivia and Landon Langenhop were diagnosed with an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesiondeficiency-1. California Proposition 14, a citizen-initiated ballot measure, authorizes bonds continuing stem cell research.(Photo: Harrison Hill, USA TODAY)
Doctors would take each childs blood cells, fix the mutationand return them. It should be a permanent fix, with less risk than a bone marrow transplantbecause the healthy cells would be their own, so their bodies wouldnt reject them as foreign.
The approach had been tried in only one child, though.
This is the type of research reaching patients nearly two decades after President George W. Bush banned federal funding of stem cell researchand 16 years after California residents approved a tax increase on themselves to support research.
Proposition 14 on Tuesday's ballot askswhether Californians want to continue this work, providing $5.5 billion for stem cell research over the next three decades.
In the early 2000s, stem cell research was controversial because it often required the destruction of human embryos. Though embryonic stem cells remain essential for some therapies, in cases such as the Langenhops', treatment focuses on manipulating a persons own cells.
Stem cell science has made tremendous progress, but as in most new fields, the pace remains painstakingly slow. Every treatment has to be the subject of years of trial-and-error research, and many scientific hurdles linger.
Stem cells have been used to treat rare diseases, such as severe combined immunodeficiency, also known as "bubble boy disease," and they are being tested in more common conditions such as Parkinson's disease, macular degeneration, Type 1 diabetesand even heart disease.
"Even if a subset of stuff in the pipeline goes all the way, it will change the world for patients who currently don't have other good options," said Sean Morrison, a stem cell biologist in Dallas.
"It's a pivotal time in the field," said Dr. Deepak Srivastava, president of the Gladstone Institutes, a nonprofit research organization based in San Francisco. "We can feel that we're at an inflection point, where after years of discovery and creating a foundation of knowledge, we're finally at a point where a number of approaches are reaching clinical trials."
The Langenhop Family temporarily relocated from Canton, Ohio, to Los Angeles, so their children could receive stem cell treatment for leukocyte adhesion deficiency-1.(Photo: Harrison Hill, USA TODAY)
Stem cell therapies haven't advanced as far as some clinics offering expensive treatments claim.
Getting stem cells injected into your knee, for example, hasn't been scientifically proven safe or effective but some clinics charge thousands of dollars for the procedure.
"There are many clinics throughout the world,including in the United States, that continue to market unproven stem cell therapies," said Timothy Caulfield, a professor of law and public health at the University of Alberta in Canada. "They leverage the excitement that has surrounded this area to push products that aren't supported by good science. Indeed, there still aren't many stem cell therapies that are clearly ready for broad clinical application."
One way to distinguish the good science from the scams, Morrison said, is to look at what's promised. Anyone who offers to treat differentailments with the same "multipurpose" cells is selling snake oil, he said.
There are a wide variety of stem cells embryonic stem cells, induced pluripotent stem cells, somatic cells, etc, he said and it's challenging to figure out which to use against which disease.
"Every disease is a different set of challenges, and we spend years trying to develop therapies that are safe and effective," said Morrison, who chairs the public policy committee of the International Society for Stem Cell Research, a scientific organization. "When a company comes out making claims about a one-size-fits-all therapy that can treat everything, that's a sure sign that they're just trying to take your money."
Several researchers interviewed by USA TODAY said state funding helped put California at the forefront of global stem cell research.
George Daley, a stem cell biologist who is dean of Harvard Medical School, said he's envious of the California researchers who have access to this pot of money.
"California has always been a very exciting place to pursue science, but prior to (the taxpayer funding), it wasn't exactly the place that was the first on the tip of your tongue as a powerhouse community for stem cell science," he said. "But there's no way that today it wouldn't be listed in the top three."
Daley, a global leader in the field, said he thinks the funding spurred enthusiasm for stem cell research more broadly. "The entire excitement around the field of stem cell biology is part of the reason you're seeing cures in cancer and impending cures in devastating diseases like sickle cell anemia,"he said.
Although stem cell therapy hasn't gotten anyone out of a wheelchair yet, he said important research continues that may eventually transform paralyzed patients' lives. "If it's taken us longer than people anticipated, that's just the pace of science," he said.
Research begun in the Harvard lab of Doug Melton may soon revolutionize the treatment of Type 1 diabetes, he said, liberating patients from needing to inject themselves daily with insulin.
Srivastava, a cardiologist, admittedthat the field, backed by federal funding, spent more than a decade chasing cardiac stem cell treatments that never succeeded, possibly because they weren't stem cells at all.
Now, his lab and others have modified true stem cells into beating heart cells, he said, which should one day be able to restore tissue damaged by a heart attack.
The big bottleneck in the field, Srivastava said, is getting cells to fully mature in a dish. Scientists can turn stem cells into immature cells of many different types neurons, heart cells, retinal cells but they get stuck in this fetal-like state.
Beating heart cells derived from stem cells can create rhythm disturbances because they're electrically different from normal, mature cells, he said.
"It would be beneficial to have a cell that could function more like a cell after birth," Srivastava said.
Donald Kohn, the Langenhops' doctor at the University of California, Los Angeles, has been involved in stem cell research since 1985.
"I've seen it go from a dream, a vision, to now just various degrees of how it's working," said Kohn, also a member of the UCLA Broad Stem Cell Research Center. About a dozen blood diseases such as LAD-1 have shown "very good clinical responses" to the type of treatment the Langenhop children received.
The children are missing a proteinin their white blood cells that would allow the cellsto reach a cut or damaged tissue. The children can't clear infections and suffer from inflammation and other immune-related problems.
Kohn's study of kids with LAD-1 mutations will eventually include nine patients. Depending on the results, the companysponsoring the trial, Rocket Pharmaceutics of New York, will ask the U.S. Food and Drug Administration for a license to sell the therapy.
Donald Kohn, the Langenhops' UCLA doctor, calls the parents "heroic."(Photo: Harrison Hill, USA TODAY)
He said he's been blown away by how well the Langenhops have dealt with the trials and tribulations of the past year.
"I just think they're heroic, what these parents are doing," Kohn said.
At first, the Langenhops asked themselves how a disease that strikes fewer than 1 in a million children could have struck them three times.
But now, more than a year after Ava's diagnosis and six months after temporarily moving to California for the treatments, Alicia and Jon just want to bring three healthy kids home to Canton, Ohio.
They flew to California for the first time last December so doctors could collect bone marrow cells from Ava. They'd planned to come back in February for the treatment, but not enough cells had been repaired, so the February trip was just a repeat of December.
By the time they were ready to come back to UCLA Mattel Children's Hospital for her therapy in late April, the pandemic had struck. The airplane was nice and empty.
Ava Langenhop receives a stem cell treatment for an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesion deficiency-1.(Photo: Courtesy of UCLA)
Ava got chemotherapy twice a day for five days to kill off her faulty white blood cells. After a day of rest, she was given back her own blood stem cells, gene-edited to remove her damaging LAD-1 mutation.
Her one complaint: the therapy smelled like creamed corn and made her gag.
She recovered quickly, and after about a month in the hospital, enough white blood cells had grown back for her to safely return to the family's rental apartment, just off the UCLA campus, where her mom has turned the living room into a classroom for the girls.
Although she lost all her hair from chemo, it's slowly growing back, and she's very proud of her cropped hairstyle, Alicia said. She picks out a bow every day to match her outfit.
At Ava's three-month checkup this summer, doctors found her bone marrow was producing healthy white blood cells. Her LAD-1 is considered eliminated and she'll never need another treatment.
"She'll probably be healthy forever," Kohn said.
Landon, age 1, completed his treatment about a month ago and was allowed out of the hospital last week. He's bald, but his blue eyes still sparkle, and as he wavedthrough the camera on a recent Zoom call, it's hard to imagine a cuter, healthier-looking baby.
Although originally slated for treatment before her brother, Olivia, 3, ended up last because, as with her sister, the processing of her cells didn't work well the first time. She went to the hospital Sunday and starts her chemo Monday night. She is scheduled to receive the corrected cells next week.
Landon Langenhop receives his stem cell treatment for leukocyte adhesion deficiency-1.(Photo: Courtesy of UCLA)
Olivia was excited to start her therapy, to be "part of the club" with her sister and brother, Alicia said. "She can't wait to turn bald."
The cost of all three children'streatments and the rental apartment and plane fare are being picked up by Rocket Pharmaceuticals. That's the upside of volunteering for clinical trials: the treatment is paid for by the sponsor.
Jon was a bank branch manager before the pandemic and now works remotely for the same bank, reviewing loan applications. "It gives me the chance to be at the hospital with whichever child is in the hospital at that time," Jon said, chuckling.
Alicia, a former teacher and day care center assistant manager, has been home-schooling the kids since the start of the pandemic.
Their doctor hopes to have the family back in Canton for Christmas or at least New Year's. The weather won't be as nice as in Southern California, but they'll be home, surrounded by their supportive family and friends. And Jon and Alicia won't have to worry anymore about every scrape and sniffle.
They don't focus much on the details of how the science works. They're just happy it has.
"We feel so fortunate to be living in a time when this is possible," Alicia said.
If they had been in this situation even a few years ago, the treatment wouldn't have existed, Jon said. If they had found out about Ava's mutation when she was younger, they wouldn't have had two more children.
"It's kind of crazy how it's all worked out for us," he said.
The strength of their kids has given them strength. "They just go with the flow. It's kind of incredible how resilient they are and can just bounce back from these hospitalizations," Jon said.
"Like nothing ever happened," Alicia added.
The three children will probably have few if any memories of their disease and treatment. For Jon and Alicia, however, this year is seared into their memory.
"It'll take us a while to realize they don't have this anymore," Jon said.
Karen Weintraub can be reached at kweintraub@usatoday.com.
Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.
The Langenhop Family plays at the Franklin D. Murphy Sculpture Garden at UCLA. Children Ava, Olivia and Landon were diagnosed with an extremely rare, inherited disorder of the white blood cells, called leukocyte adhesiondeficiency-1. California Proposition 14, a citizen-initiated ballot measure that will appear on the ballot in the 2020, authorizes Bonds continuing Stem Cell Research. A Yes vote will allow researchers to continue studying and working towards finding cures for individuals like Ava, Olivia and Landon.(Photo: Harrison Hill, USA TODAY)
Read or Share this story: https://www.usatoday.com/story/news/health/2020/11/02/stem-cell-therapy-californias-prop-14-seeks-tax-money-research-ucla/6049101002/
- CAR T cell therapy explained: Cancer types, success rate, and more - Medical News Today - March 24th, 2021
- UK deal sees consolidation of two players in the iPSC space - BioPharma-Reporter.com - March 24th, 2021
- FDA Approves Merck's KEYTRUDA (pembrolizumab) Plus Platinum- and Fluoropyrimidine-Based Chemotherapy for Treatment of Certain Patients With Locally... - March 24th, 2021
- Stem Cell Therapy Market Evaluation of Industry Trends, Growth Drivers and Forecast To 2025 NeighborWebSJ - NeighborWebSJ - February 25th, 2021
- Injectable hydrogel with MSNs/microRNA-21-5p delivery enables both immunomodification and enhanced angiogenesis for myocardial infarction therapy in... - February 25th, 2021
- Scientists have Created a 'Brain in a Dish.' It Could Potentially Cure Alzheimer, Dementia - News18 - February 25th, 2021
- Exosome therapeutic Market Segmentation, Parameters, Prospects 2021 And Forecast Research Report To 2027 KSU | The Sentinel Newspaper - KSU | The... - February 25th, 2021
- 2021 Updates in Autologous Stem Cell Based Therapies Industry with Global Market Demand Analysis, Industry Chain, Revenue and Forecast 2026 - The... - February 25th, 2021
- [Full text] A Comprehensive Review on Factors Influences Biogenesis, Functions, Th | IJN - Dove Medical Press - February 17th, 2021
- Energy drinks may damage the heart, researchers warnshould the FDA get involved? - Cardiovascular Business - February 17th, 2021
- bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) - BioSpace - February 17th, 2021
- Beti-Cel Gene Therapy Frees Patients With Beta-Thalassemia From Red Blood Cell Transfusions - OncLive - February 17th, 2021
- Worldwide Cell Therapy Industry to 2027 - Profiling Allosource, Medipost and Mesoblast Among Others - PRNewswire - February 9th, 2021
- Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - Yahoo Finance UK - February 4th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 4th, 2021
- Stem Cell Study Illuminates the Cause of a Devastating Inherited Heart Disorder - Newswise - February 1st, 2021
- Merck Receives Positive EU CHMP Opinion for Expanded Approval of KEYTRUDA (pembrolizumab) in Certain Patients With Relapsed or Refractory Classical... - February 1st, 2021
- Worldwide Industry for Biopreservation to 2026 - Key Drivers, Restraints and Opportunities - Yahoo Finance - January 5th, 2021
- Vape Flavorings Are Cardiotoxic and Can Damage the Heart - SciTechDaily - December 28th, 2020
- Outlook on the Biopreservation Global Market to 2026 - Profiling Avantor, BioLife Solutions and ThermoGenesis Among Others - GlobeNewswire - December 26th, 2020
- UC Davis researchers find a way to help stem cells work ... - December 17th, 2020
- I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic - PRNewswire - December 17th, 2020
- Flavors added to vaping devices damage the heart, vanilla custard the most toxic of all - Study Finds - December 17th, 2020
- Covid-19 can have impact on heart too, say experts - Hindustan Times - December 17th, 2020
- Network of Genes Involved in Congenital Heart Disease Identified - Technology Networks - December 17th, 2020
- Industry News: Hamamatsu Photonics UK Ltd and the Medical Technologies Innovation Facility enter into a partnership agreement - SelectScience - December 17th, 2020
- Osteoporosis treatments could be on the way after scientists identify aging gene - iNews - November 30th, 2020
- Global Myocardial Infarction Drug Market to have sustainable growth over the forecast period 2020-2028| Leading Players BioCardia, Inc., Laboratoires... - November 30th, 2020
- Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice - November 24th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 24th, 2020
- Autologous Stem Cell Based Therapies Market Share, Growth by Top Company, Region, Application, Driver, Trends & Forecasts by 2026 - PRnews Leader - November 24th, 2020
- 3D Cardiac Mapping Systems Market Competitive Landscape Analysis with Forecast by 2028 - The Haitian-Caribbean News Network - November 24th, 2020
- Organoids mimic the early development of the heart in mouse embryos - BioNews - November 18th, 2020
- Mimicking the early development of the heart - Tech Explorist - November 18th, 2020
- Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.com - Business Wire - November 18th, 2020
- UPDATED: Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? - Endpoints News - November 18th, 2020
- Can Hearts Repair Themselves Via Stem Cells - The Niche - November 13th, 2020
- Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs ... - November 13th, 2020
- Global Autologous Stem Cell Based Therapies Market 2020 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2025 - The... - November 13th, 2020
- The Amniotic Fluid Stem Cell Therapy market to be in conjunction to growth from 2018 to 2026 - PRnews Leader - November 13th, 2020
- BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights - GlobeNewswire - November 13th, 2020
- Exploring Genetic Variation and COVID-19 Clinical Variability - Technology Networks - November 13th, 2020
- Autologous Stem Cell Based Therapies Market 2020 Emerging Trend and Advancement - News by aeresearch - November 10th, 2020
- KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall... - November 10th, 2020
- Global Progenitor Cell Product Professional Survey 2020 by Manufacturers, Regions, Types and Applications, Forecast to 2026 - Zenit News - November 10th, 2020
- Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients... - November 10th, 2020
- Advancement: Know the Rapid Growth Factors of Biopreservation Market| Stay Up-To-Date With Emerging - PharmiWeb.com - November 10th, 2020
- Stem Cell Therapy Market is estimated to be worth USD 8.5 Billion by 2030 - PRnews Leader - November 4th, 2020
- Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition - Business Wire - November 4th, 2020
- Stem Cell Therapy Market to Surge at a Robust Pace in Terms of Revenue Over2017 2025 - Royal Sutton News - November 4th, 2020
- Autologous Stem Cell Based Therapies Market to Witness Increase in Revenues by 2020-2026 - PRnews Leader - November 3rd, 2020
- Orphan Drug Designation Granted for CSL Behring's Investigational Plasma-Derived Hemopexin Therapy for Sickle Cell Disease - PRNewswire - November 3rd, 2020
- Ready To Use Autologous Stem Cell Based Therapies Market Industry Analysis, Trend and Growth, 2020-2020 - Royal Sutton News - November 1st, 2020
- Novartis expands Kymriah manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - GlobeNewswire - November 1st, 2020
- Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser - November 1st, 2020
- The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients - DocWire News - October 23rd, 2020
- COVID-19 can affect the heart - Science Magazine - October 23rd, 2020
- Stem Cell Assay Market expected to Witness a Sustainable Growth over 2025 - TechnoWeekly - October 23rd, 2020
- Exosome Therapeutic Market 2020-2026 Demand Analysis and Projected Huge Growth by Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 23rd, 2020
- Stem Cell Assay Market In-Depth Analysis & Forecast 2017-2025 - The Think Curiouser - October 22nd, 2020
- Five Indian American Researchers Named Among NIH 2020 New Innovator Awardees - India West - October 22nd, 2020
- Exosome Therapeutic Market 2020-2026 to Witness Excellent Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,... - October 22nd, 2020
- Banking wisdom: Teen saving stem cells in hopes of future treatment - LubbockOnline.com - October 16th, 2020
- Global Cell Based Assay & High Content Screening Markets to 2024: Updated Report - Understand Growth Expectations and the Potential Market Size -... - October 16th, 2020
- Merck Presents Three-Year Survival Data for KEYTRUDA (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational... - October 16th, 2020
- Preclinical Study Shows Improvement In Recovery From Heart Attack With Exosomes - Anti Aging News - October 10th, 2020
- Autologous Stem Cell Based Therapies Market Size, Business Revenue Forecast, Leading Competitors And Growth Trends 2026| Regeneus, Mesoblast,... - October 10th, 2020
- Recording thousands of nerve cell impulses at high resolution - Newswise - October 4th, 2020
- Wisconsin Medicine Livestream: The future of medicine - Wisbusiness.com - October 2nd, 2020
- Measuring chips amplify and record nerve cells - Futurity: Research News - October 2nd, 2020
- Recording thousands of nerve cell impulses at high resolution - ScienceDaily - Up News Info - October 2nd, 2020
- Kyoto University project aims to supply iPS cells widely at low cost - The Japan Times - September 30th, 2020
- Heart attack patches may save lives in US and beyond - Galveston County Daily News - September 30th, 2020
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2025 Global Briefing, Growth Analysis And Opportunities Outlook | Major Giants ... - September 30th, 2020
- Exosome Therapeutic Market Latest Industry Size, Growth, Share, Emerging Demands, and Competitive Landscape || Major Gaints Jazz Pharmaceuticals,... - September 30th, 2020
- James T. Willerson, Revered Clinician, Editor, and Mentor, Dies at 81 - TCTMD - September 22nd, 2020
- Researchers Discover a Way To Create Induced Tropoblast Stem Cells - Technology Networks - September 18th, 2020
- What Is Covid-19 Doing to Our Hearts? - The New Republic - September 18th, 2020
- Astellas and Seattle Genetics Announce PADCEV (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated... - September 18th, 2020
- Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis - BioSpace - September 14th, 2020